The FDA has approved Xipere for suprachoroidal use in the treatment of macular edema associated with uveitis, according to a press release from Bausch + Lomb and Clearside Biomedical.
Xipere (triamcinolone acetonide injectable suspension) is the first approved treatment to use the suprachoroidal space as a delivery pathway for the treatment of macular edema associated with uveitis, the release said.
“The utilization of the suprachoroidal space provides targeted delivery and compartmentalization of medication,” Joseph C. Papa, chairman and CEO of Bausch Health, said in the release. “The